Premium
Extracellular nicotinamide phosphoribosyltransferase, a new cancer metabokine
Author(s) -
Grolla Ambra A,
Travelli Cristina,
Genazzani Armando A,
Sethi Jaswinder K
Publication year - 2016
Publication title -
british journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.432
H-Index - 211
eISSN - 1476-5381
pISSN - 0007-1188
DOI - 10.1111/bph.13505
Subject(s) - nicotinamide phosphoribosyltransferase , cancer , cancer research , medicine , nicotinamide mononucleotide , cytokine , biology , endocrinology , nad+ kinase , enzyme , nicotinamide adenine dinucleotide , biochemistry
In this review, we focus on the secreted form of nicotinamide phosphoribosyltransferase (NAMPT); extracellular NAMPT (eNAMPT), also known as pre‐B cell colony‐enhancing factor or visfatin. Although intracellular NAMPT is a key enzyme in controlling NAD metabolism, eNAMPT has been reported to function as a cytokine, with many roles in physiology and pathology. Circulating eNAMPT has been associated with several metabolic and inflammatory disorders, including cancer. Because cytokines produced in the tumour micro‐environment play an important role in cancer pathogenesis, in part by reprogramming cellular metabolism, future improvements in cancer immunotherapy will require a better understanding of the crosstalk between cytokine action and tumour biology. In this review, the knowledge of eNAMPT in cancer will be discussed, focusing on its immunometabolic function as a metabokine , its secretion, its mechanism of action and possible roles in the cancer micro‐environment.